0001661053 2025-01-01 2025-06-30 0001661053 2025-07-29 0001661053 2025-06-30 0001661053 2024-12-31 0001661053 2025-04-01 2025-06-30 0001661053 2024-04-01 2024-06-30 0001661053 2024-01-01 2024-06-30 0001661053 us-gaap:CommonStockMember 2025-03-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001661053 us-gaap:RetainedEarningsMember 2025-03-31 0001661053 2025-03-31 0001661053 us-gaap:CommonStockMember 2024-03-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001661053 us-gaap:RetainedEarningsMember 2024-03-31 0001661053 2024-03-31 0001661053 us-gaap:CommonStockMember 2024-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001661053 us-gaap:RetainedEarningsMember 2024-12-31 0001661053 us-gaap:CommonStockMember 2023-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001661053 us-gaap:RetainedEarningsMember 2023-12-31 0001661053 2023-12-31 0001661053 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001661053 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001661053 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001661053 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001661053 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001661053 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001661053 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001661053 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001661053 us-gaap:CommonStockMember 2025-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001661053 us-gaap:RetainedEarningsMember 2025-06-30 0001661053 us-gaap:CommonStockMember 2024-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001661053 us-gaap:RetainedEarningsMember 2024-06-30 0001661053 2024-06-30 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2025-06-30 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2024-12-31 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2025-06-30 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001661053 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-04-01 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0001661053 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0001661053 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001661053 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001661053 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001661053 2021-12-31 0001661053 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001661053 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001661053 NVNO:EmployeeExpenseMember 2025-04-01 2025-06-30 0001661053 NVNO:EmployeeExpenseMember 2024-04-01 2024-06-30 0001661053 NVNO:EmployeeExpenseMember 2025-01-01 2025-06-30 0001661053 NVNO:EmployeeExpenseMember 2024-01-01 2024-06-30 0001661053 NVNO:ClinicalMember 2025-04-01 2025-06-30 0001661053 NVNO:ClinicalMember 2024-04-01 2024-06-30 0001661053 NVNO:ClinicalMember 2025-01-01 2025-06-30 0001661053 NVNO:ClinicalMember 2024-01-01 2024-06-30 0001661053 NVNO:ProductsMember 2025-04-01 2025-06-30 0001661053 NVNO:ProductsMember 2024-04-01 2024-06-30 0001661053 NVNO:ProductsMember 2025-01-01 2025-06-30 0001661053 NVNO:ProductsMember 2024-01-01 2024-06-30 0001661053 NVNO:OtherMember 2025-04-01 2025-06-30 0001661053 NVNO:OtherMember 2024-04-01 2024-06-30 0001661053 NVNO:OtherMember 2025-01-01 2025-06-30 0001661053 NVNO:OtherMember 2024-01-01 2024-06-30 0001661053 NVNO:ProfessionalFeesMember 2025-04-01 2025-06-30 0001661053 NVNO:ProfessionalFeesMember 2024-04-01 2024-06-30 0001661053 NVNO:ProfessionalFeesMember 2025-01-01 2025-06-30 0001661053 NVNO:ProfessionalFeesMember 2024-01-01 2024-06-30 0001661053 NVNO:ReserveForUncollectiblePrepaidClinicalCostsMember 2025-04-01 2025-06-30 0001661053 NVNO:ReserveForUncollectiblePrepaidClinicalCostsMember 2024-04-01 2024-06-30 0001661053 NVNO:ReserveForUncollectiblePrepaidClinicalCostsMember 2025-01-01 2025-06-30 0001661053 NVNO:ReserveForUncollectiblePrepaidClinicalCostsMember 2024-01-01 2024-06-30 0001661053 NVNO:OccupanciesMember 2025-04-01 2025-06-30 0001661053 NVNO:OccupanciesMember 2024-04-01 2024-06-30 0001661053 NVNO:OccupanciesMember 2025-01-01 2025-06-30 0001661053 NVNO:OccupanciesMember 2024-01-01 2024-06-30 0001661053 NVNO:InsuranceMember 2025-04-01 2025-06-30 0001661053 NVNO:InsuranceMember 2024-04-01 2024-06-30 0001661053 NVNO:InsuranceMember 2025-01-01 2025-06-30 0001661053 NVNO:InsuranceMember 2024-01-01 2024-06-30 iso4217:USD shares iso4217:USD shares pure false --12-31 Q2 0001661053

10-Q true 2025-06-30 2025 false 001-38325 enVVeno Medical Corporation DE 33-0936180 70 Doppler Irvine CA 92618 (949) 261-2900 Common Stock, $0.00001 par value NASDAQ NVNO Yes Yes Non-accelerated Filer true false false 19247141

2044000

1754000

33098000

41399000

462000

581000

35604000

43734000

113000

182000

829000

1007000

31000 31000

36577000

44954000

2638000

1731000

377000

364000

3015000

2095000

505000

700000

3520000

2795000

0.00001

10000000

0.00001

250000000

19247000

17536000

196109000

194014000

-163052000

-151855000

33057000

42159000

36577000

44954000

2891000

2825000

5448000

5877000

4158000

2629000

6555000

5080000

-7049000

-5454000

-12003000

-10957000

239000

379000

665000

787000

-79000

46000

-273000

90000

195000

73000

414000

132000

355000

498000

806000

1009000

-6694000

-4956000

-11197000

-9948000

-0.33

-0.31

-0.55

-0.62

20352000

16067000

20352000

16062000

17536000

194665000

-156358000

38307000

1711000

1444000

-6694000

19247000

196109000

-163052000

33057000

13330000

177397000

-135028000

42369000

1005000

-4956000

13330000

178402000

-139984000

38418000

17536000

194014000

-151855000

42159000

2095000

1711000

-11197000

19247000

196109000

-163052000

33057000

13317000

176236000

-130036000

46200000

13317000

176236000

-130036000

46200000

2120000

13000

46000

-9948000

13330000

178402000

-139984000

38418000

13330000

178402000

-139984000

38418000

-11197000

-9948000

2095000

2120000

74000

106000

178000

171000

-273000

90000

-119000

-42000

907000

311000

-182000

-169000

-7733000

-7457000

24835000

31263000

5000

24000

16807000

25068000

8023000

6171000

46000

290000

-1240000

1754000

3620000

2044000

2380000

<p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zWKy7G4pNon1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 1 – Business Organization and Nature of Operations enVVeno Medical Corporation (the “Company”) is a late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (“CVI”) of the deep venous system of the leg. The Company’s lead product is the VenoValve®, a potential first of its kind surgical replacement venous valve currently in post-enrollment follow-up of its U.S. pivotal study. The Company is also developing a second product called enVVe®, a next-generation, non-surgical, transcatheter based replacement venous valve system consisting of the enVVe valve, the enVVe delivery system, and the delivery system accessories. The Company is currently conducting pre-clinical testing on enVVe. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The VenoValve and enVVe are being developed first for approval by the U.S. Food and Drug Administration (“FDA”). We expect the VenoValve to be eligible for FDA approval first, followed two to three years later by enVVe. If approved, we expect the VenoValve and enVVe to co-exist, with the VenoValve as a surgical replacement venous valve option and enVVe as a non-surgical replacement venous valve option.

<p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z0Az9LObMOk6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 2 – Management’s Liquidity Plan As of June 30, 2025, the Company had a cash and investment balance of $35.1 million and working capital of $32.6 million. Although the Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to sustain its operations, pursue its product development initiatives and penetrate markets for the sale of its products, management believes that the Company’s capital resources are sufficient to meet its obligations as they become due within one year after the date of this Quarterly Report, and sustain operations.

35100000

32600000

Note 3 – Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, such statements include all adjustments (consisting of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed financial statements of the Company as of June 30, 2025 and December 31, 2024, and for the three and six months ended June 30, 2025 and 2024. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the operating results for the full year. These unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K/A filed with the SEC on February 28, 2025. The accompanying condensed balance sheet as of December 31, 2024 has been derived from the Company’s audited financial statements.

Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, such statements include all adjustments (consisting of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed financial statements of the Company as of June 30, 2025 and December 31, 2024, and for the three and six months ended June 30, 2025 and 2024. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the operating results for the full year. These unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K/A filed with the SEC on February 28, 2025. The accompanying condensed balance sheet as of December 31, 2024 has been derived from the Company’s audited financial statements.

<p id="xdx_80E_eus-gaap--InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_zCU6MmTILikb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 4 – Investments The components of investments at June 30, 2025 and December 31, 2024 were as follows: Schedule of Components of Investments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cash Equivalents</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cash Equivalents</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair Value Level 1</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. Government securities</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zovBS82Ao6T2" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Cash equivalents">1,465</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zyvyMOfcCpgd" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Short-term investments">33,098</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zeorSAyq45M5" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Cash equivalents">1,352</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zKvuTuK0e1Q6" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Short-term investments">41,399</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total debt investments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z2y31Kjw9mnk" style="border-bottom: Black 1pt solid; text-align: right" title="Cash equivalents">1,465</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zucIcUr9oAm" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments">33,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z0J4b9e53zOi" style="border-bottom: Black 1pt solid; text-align: right" title="Cash equivalents">1,352</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zCWZ1GLdvhDe" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments">41,399</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Unrealized and realized gains and losses on the accompanying statement of operations result from fixed-income securities and are primarily attributable to changes in interest rates. Management does not believe any remaining unrealized losses represent impairments based on its evaluation of available evidence.

The components of investments at June 30, 2025 and December 31, 2024 were as follows: Schedule of Components of Investments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cash Equivalents</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cash Equivalents</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair Value Level 1</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. Government securities</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zovBS82Ao6T2" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Cash equivalents">1,465</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zyvyMOfcCpgd" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Short-term investments">33,098</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zeorSAyq45M5" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Cash equivalents">1,352</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zKvuTuK0e1Q6" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Short-term investments">41,399</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total debt investments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z2y31Kjw9mnk" style="border-bottom: Black 1pt solid; text-align: right" title="Cash equivalents">1,465</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zucIcUr9oAm" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments">33,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z0J4b9e53zOi" style="border-bottom: Black 1pt solid; text-align: right" title="Cash equivalents">1,352</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zCWZ1GLdvhDe" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments">41,399</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1465000

33098000

1352000

41399000

1465000

33098000

1352000

41399000

Note 5 – Concentrations The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. There were aggregate uninsured cash balances of $0.7 million and $0.9 million as of June 30, 2025 and December 31, 2024, respectively.

250000

700000

900000

<p id="xdx_806_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zCoIga2MrWZ7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 6 – Accounts Payable Accrued Expenses and Other Current Liabilities <p id="xdx_898_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFr2JtNOtwog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As of June 30, 2025, and December 31, 2024, accounts payable, accrued expenses and other current liabilities consist of the following: Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250630_zwxxwdith7V4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231_zflrzbe3lllg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maALAOLzCZ3_znKjFMES4VEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,073</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,006</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WorkersCompensationLiabilityCurrent_iI_pn3n3_maALAOLzCZ3_zwwl4NmHgupe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued compensation costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--AccruedClinicalCosts_iI_pn3n3_maALAOLzCZ3_zClDTdTKL0ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued clinical costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedSeverance_iI_pn3n3_maALAOLzCZ3_ztjcpyVxxXo6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued severance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALAOLzCZ3_znwaQX6jLLnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">103</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">121</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtALAOLzCZ3_zVpLVZh28Eef" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accounts payable, accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,731</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_898_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFr2JtNOtwog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As of June 30, 2025, and December 31, 2024, accounts payable, accrued expenses and other current liabilities consist of the following: Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250630_zwxxwdith7V4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231_zflrzbe3lllg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maALAOLzCZ3_znKjFMES4VEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,073</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,006</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WorkersCompensationLiabilityCurrent_iI_pn3n3_maALAOLzCZ3_zwwl4NmHgupe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued compensation costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--AccruedClinicalCosts_iI_pn3n3_maALAOLzCZ3_zClDTdTKL0ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued clinical costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedSeverance_iI_pn3n3_maALAOLzCZ3_ztjcpyVxxXo6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued severance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALAOLzCZ3_znwaQX6jLLnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">103</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">121</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtALAOLzCZ3_zVpLVZh28Eef" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accounts payable, accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,731</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1073000

1006000

629000

604000

576000 257000

103000

121000

2638000

1731000

<p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zktd6uk0CcG3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 7 – Commitments and Contingencies Litigations Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Note 8 –Stockholders’ Equity Omnibus Incentive Plan Stock Options Stock-based compensation expense is reflected in selling, general and administrative expenses in the accompanying condensed statements of operations and was $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pn5n6_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zb3X5StfyBL1" title="Stock-based compensation">1.4 million and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDCVTm1Bqxld" title="Stock-based compensation">1.0 million during the three months ended June 30, 2025 and 2024, respectively, and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zw2OEjlTJYrk" title="Stock-based compensation"><span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znekynCWfoPf" title="Stock-based compensation">2.1 million during the six months ended June 30, 2025 and 2024. As of June 30, 2025, there was $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNJI2DNVc6H3" title="Unrecognized stock-based compensation expense">4.4 million of unrecognized stock-based compensation expense related to outstanding stock options that will be recognized over the weighted average remaining vesting period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO9QN42XKAO9" title="Weighted average remaining vesting period">2.02 years. There were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEPBTFDA8ILb" title="Shares granted"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjMl5fIWsBIl" title="Shares granted">600,000 and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbZONIRaXaz6" title="Shares granted"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvI8sjEOhrc5" title="Shares granted">423,000 options granted during the three and six months ended June 30, 2025 and 2024, respectively, in connection with entering into certain employment and consulting agreements. There were approximately <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6PgIFt5Mek9" title="Shares forfeited"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxYjKQ9i2MEk" title="Shares forfeited">529,000 option grants forfeited during the three and six months ended June 30, 2025. There were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpXGRgV0eVti" title="Shares forfeited">19,000 and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVoKKnPPncn5" title="Shares forfeited">42,000 option grants forfeited during the three and six months ended June 30, 2024. There were no option grants exercised during the three and six months ended June 30, 2025. There were no option grants exercised during the three months ended June 30, 2024 and there were 13,000 option grants exercised during the six months ended June 30, 2024. Restricted Stock Units Restricted stock unit vesting is conditioned on achieving the Pre-Market Approval of the VenoValve milestone. During the three and six months ended June 30, 2025, there were <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ7quephzZl3" title="Restricted stock units forfeited in connection"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zY9aw7bg8Ir1" title="Restricted stock units forfeited in connection">50,000 restricted stock units forfeited in connection with employment termination. No expense has been recorded as of June 30, 2025. Warrants Pre-funded warrants issued in 2023 and 2021 totaling approximately 861,000 and 850,000 units, respectively, were exercised during the three and six months ended June 30, 2025, at an exercise price of $0.0001 per share.

1400000

1000000.0

2100000

4400000

P2Y7D

600000000

423000000

529000000

19000000

42000000

13000000

50000000

861000000

850000000

0.0001

Note 9 – Net Loss per Share <p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z0ILAnQ3LXOg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of June 30, 2025 and 2024: Schedule of Potentially Dilutive Common Stock Equivalents Excluded From Calculation of Diluted Net Loss Per Common Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250101__20250630_zggMTTwynei8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20240630_zLK5cMVCsG27" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5oAAXIJkIV3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares of common stock issuable upon exercise of warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">9,447</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">9,546</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zR7GJVjxUI6c" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Shares of common stock issuable upon exercise of options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,343</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,554</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zZLCYPVbFJq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive common stock equivalents excluded from diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">15,790</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">15,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z0ILAnQ3LXOg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of June 30, 2025 and 2024: Schedule of Potentially Dilutive Common Stock Equivalents Excluded From Calculation of Diluted Net Loss Per Common Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250101__20250630_zggMTTwynei8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20240630_zLK5cMVCsG27" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5oAAXIJkIV3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares of common stock issuable upon exercise of warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">9,447</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">9,546</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zR7GJVjxUI6c" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Shares of common stock issuable upon exercise of options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,343</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,554</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zZLCYPVbFJq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive common stock equivalents excluded from diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">15,790</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">15,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

9447000

9546000

6343000

5554000

15790000

15100000

Note 10 – Segment Reporting The Company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States. The accounting policies of the segment are the same as those described in the summary of significant accounting policies set forth in the Company’s Form 10-K/A, filed with the SEC on February 28, 2025. Since the Company operates in a single segment, the measure of segment total assets and loss from operations is the same as that reported on the accompanying balance sheets as total assets, and the accompanying statement of operations as loss from operations, respectively. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM uses operating expenses to measure performance against progress in its clinical trials and its product development. The following table sets forth segment expenses. <p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zX7dGLVRyoR9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Schedule of Segment Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="font-style: italic">(In thousands)</td> <td> </td> <td id="xdx_495_20250401__20250630_z3iFueUvsldb" style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td id="xdx_49A_20240401__20240630_zMT1AvQdeCB6" style="text-align: right"> </td> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20250101__20250630_zvjbfHEPgCB3" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20240101__20240630_zDI0EAd89cu9" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Three Months Ended June 30,</td> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended June 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td> <td style="padding-bottom: 1pt"></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Research and Development:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--EmployeeExpenseMember_zqL4r3BIyXui" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 37%; text-align: left">Employee expense</td> <td style="width: 2%">$</td> <td style="text-align: right; width: 12%">1,329</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 12%">1,211</td> <td style="width: 1%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,699</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,364</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalMember_zJWIMWryBZC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Clinical</td> <td> </td> <td style="text-align: right">960</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,198</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,832</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,657</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ProductsMember_zSbDTPl1Imul" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Product</td> <td> </td> <td style="text-align: right">403</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">548</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">576</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_z7sE8l9nKodk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">199</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">143</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">369</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">280</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_msOILzwMI_zmb6xOpwzii7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total research and development</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">2,891</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">2,825</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,448</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,877</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Selling, General and Administrative Expense:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--EmployeeExpenseMember_zz5YQ7rgece2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Employee expense</td> <td> </td> <td style="text-align: right">2,310</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,432</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,895</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ProfessionalFeesMember_zE7lnIiN3Nsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Professional fees</td> <td> </td> <td style="text-align: right">308</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">517</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">888</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">932</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ReserveForUncollectiblePrepaidClinicalCostsMember_zv7UyAJIu9hc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reserve for uncollectible prepaid clinical costs</td> <td> </td> <td style="text-align: right">626</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OccupanciesMember_z3GfjncWYXz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Occupancy</td> <td> </td> <td style="text-align: right">151</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">156</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--InsuranceMember_zuBKQGdADnwl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Insurance</td> <td> </td> <td style="text-align: right">157</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">164</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">320</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">329</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zgGjS5FMNra7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">606</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">360</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">863</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">615</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_msOILzwMI_zgWOZkv2Oe0e" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total selling, general and administrative expense</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">4,158</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">2,629</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,555</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,080</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iNT_pn3n3_di_mtOILzwMI_maNILzmHo_zFoif85qHo39" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Loss from Operations</td> <td> </td> <td style="text-align: right">7,049</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,454</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,003</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,957</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01N_pn3n3_di_maNILzmHo_zNApSF6HKtUg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Adjustments and reconciling items</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(355</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(498</td> <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(806</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,009</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzmHo_z4J7eAYOHGRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">6,694</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,956</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,197</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,948</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Adjustments and reconciling items between loss from operations and net loss consist of interest income and realized and unrealized gains and losses related to the Company’s investments in US Treasury securities.

<p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zX7dGLVRyoR9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Schedule of Segment Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="font-style: italic">(In thousands)</td> <td> </td> <td id="xdx_495_20250401__20250630_z3iFueUvsldb" style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td id="xdx_49A_20240401__20240630_zMT1AvQdeCB6" style="text-align: right"> </td> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20250101__20250630_zvjbfHEPgCB3" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20240101__20240630_zDI0EAd89cu9" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Three Months Ended June 30,</td> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended June 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td> <td style="padding-bottom: 1pt"></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Research and Development:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--EmployeeExpenseMember_zqL4r3BIyXui" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 37%; text-align: left">Employee expense</td> <td style="width: 2%">$</td> <td style="text-align: right; width: 12%">1,329</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 12%">1,211</td> <td style="width: 1%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,699</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,364</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalMember_zJWIMWryBZC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Clinical</td> <td> </td> <td style="text-align: right">960</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,198</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,832</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,657</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ProductsMember_zSbDTPl1Imul" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Product</td> <td> </td> <td style="text-align: right">403</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">548</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">576</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_z7sE8l9nKodk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">199</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">143</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">369</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">280</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_msOILzwMI_zmb6xOpwzii7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total research and development</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">2,891</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">2,825</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,448</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,877</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Selling, General and Administrative Expense:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--EmployeeExpenseMember_zz5YQ7rgece2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Employee expense</td> <td> </td> <td style="text-align: right">2,310</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,432</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,895</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ProfessionalFeesMember_zE7lnIiN3Nsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Professional fees</td> <td> </td> <td style="text-align: right">308</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">517</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">888</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">932</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ReserveForUncollectiblePrepaidClinicalCostsMember_zv7UyAJIu9hc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reserve for uncollectible prepaid clinical costs</td> <td> </td> <td style="text-align: right">626</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OccupanciesMember_z3GfjncWYXz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Occupancy</td> <td> </td> <td style="text-align: right">151</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">156</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--InsuranceMember_zuBKQGdADnwl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Insurance</td> <td> </td> <td style="text-align: right">157</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">164</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">320</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">329</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zgGjS5FMNra7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">606</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">360</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">863</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">615</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_msOILzwMI_zgWOZkv2Oe0e" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total selling, general and administrative expense</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">4,158</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">2,629</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,555</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,080</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iNT_pn3n3_di_mtOILzwMI_maNILzmHo_zFoif85qHo39" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Loss from Operations</td> <td> </td> <td style="text-align: right">7,049</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,454</td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,003</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,957</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01N_pn3n3_di_maNILzmHo_zNApSF6HKtUg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Adjustments and reconciling items</td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(355</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(498</td> <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(806</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,009</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzmHo_z4J7eAYOHGRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">6,694</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,956</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,197</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,948</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1329000

1211000

2699000

2364000

960000

1198000

1832000

2657000

403000

273000

548000

576000

199000

143000

369000

280000

2891000

2825000

5448000

5877000

2310000

1432000

3544000

2895000

308000

517000

888000

932000

626000

151000

156000

314000

309000

157000

164000

320000

329000

606000

360000

863000

615000

4158000

2629000

6555000

5080000

-7049000

-5454000

-12003000

-10957000

355000

498000

806000

1009000

-6694000

-4956000

-11197000

-9948000

June 12, 2025 Dr. Francis Duhay director true September 30, 2026 20000